Clinical Characteristics and Prognostic Values of PIK3CA Mutation in Colorectal Cancer Patients

Clinical Characteristics and Prognostic Values of PIK3CA Mutation in Colorectal Patients. Clinical Therapeutics (2022): Abstract Objective: This study aimed to investigate the role of PIK3CA mutation in the prognosis of Colorectal Cancer (CRC). Methods: The clinical data of 386 CRC patients who underwent next-generation sequencing (NGS) test in the First Affiliated Hospital of Zhengzhou University from January 2017 to December 2020 were retrospectively reviewed. The associations between PIK3CA mutation and clinicopathologic characteristics of CRC patients were analyzed by chi-square test and Fisher’s exact test. Kaplan-Meier curves and Cox models were conducted to assess possible prognostic values of PIK3CA mutation. Results: PIK3CA mutation was found in 88 (22.8%) of the 386 CRC patients. The percentage of MSI-H in PIK3CA mutated patients were higher than that in PIK3CA wild-type patients (P < 0.0001). The Median Overall Survival (mOS) of patients with PIK3CA mutation was significantly higher than that of wild-type patients (P = 0.0112). The progression free survival (PFS) of the mutated patients was also significantly prolonged compared with that of the wild type (P = 0.0132). Results of multivariate analysis showed that PIK3CA wild-type was independent risk factor for the survival of CRC patients. Conclusion: PIK3CA mutation had an important impact on the clinic pathologic features and the prognosis for CRC patients. The survival of PIK3CA mutated patients was significantly prolonged, which needs further studies of large sample size, and long follow-up period to provide robust evidence.